FBDT
FBDTCIK 0001892704
Micro
Revenue $384K
Assets $18M
as of Sep 13, 2026
Every 8-K is open in full. Other 10-Ks and 10-Qs show a 3-bullet preview. A free account reads 3 more full reports a month. Generating a report requires a verified account.
Sign up freeWant to see a complete report first? Today's free report (FUL 10-Q) is open in full — no account needed.
8-K
Filed Sep 23, 2026
· Period ending Sep 23, 2026
Summary not yet generated.
424B5
Filed Sep 11, 2026
Summary not yet generated.
Partner
Trade FBDT commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
S-1
Filed Sep 2, 2026
Summary not yet generated.
8-K
Filed Sep 1, 2026
· Period ending Sep 1, 2026
Summary not yet generated.
424B4
Filed Aug 31, 2026
Red flag
FBDT files 424B4 prospectus; terms not priced, offering size not specified
6 material changes detected. Sign up free to read the summary.
10-Q
Filed Aug 28, 2026
· Period ending Jun 30, 2026
Summary not yet generated.
8-K
Filed Aug 25, 2026
· Period ending Aug 25, 2026
Summary not yet generated.
424B4
Filed Aug 20, 2026
Summary not yet generated.
S-1/A
Filed Aug 7, 2026
Standing risk
FBDT adds Nasdaq listing risk disclosures in latest S-1/A
5 material changes detected. Sign up free to read the summary.
S-1/A
Filed Aug 3, 2026
Summary not yet generated.
S-1/A
Filed Jun 12, 2026
Summary not yet generated.
S-1
Filed Apr 30, 2026
Summary not yet generated.
Latest financial statements
From 10-Q filed Aug 28, 2026 (period ending Jun 30, 2026). As printed on the EDGAR/iXBRL face — not generated by the model.
Condensed Statements of Operations (Unaudited)
| Description | Three months ended June 30, 2026 | Three months ended June 30, 2025 | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|---|---|
| Net revenues | 95,353 | 95,219 | 361,357 | 110,905 |
| Cost of revenues | 605,866 | 592,348 | 1,235,716 | 919,844 |
| Net loss associated with liquidation of raw materials | — | 298,771 | — | 684,960 |
| Gross margin | (510,513) | (795,900) | (874,359) | (1,493,899) |
| Operating expenses: | ||||
| Selling, general, and administrative expense | 11,202,485 | 873,299 | 25,288,394 | 1,345,881 |
| Research and development | 126,313 | — | 126,313 | — |
| Total operating expenses | 11,328,798 | 873,299 | 25,414,707 | 1,345,881 |
| Loss from operations | (11,839,311) | (1,669,199) | (26,289,066) | (2,839,780) |
| Other expense, net: | ||||
| Interest expense, net | (1,860,323) | (582,123) | (2,004,679) | (988,452) |
| Amortization of deferred financing costs | (191,590) | — | (191,590) | — |
| Change in fair value of warrant liability | 45,094 | — | 45,094 | — |
| Loss on sale of assets | (16,758) | (1,906) | (56,215) | (1,906) |
| Other income | — | 25,500 | — | 42,500 |
| Other expense | (13,389) | (10,260) | (26,776) | (20,525) |
| Total other expense, net | (2,036,966) | (568,789) | (2,234,166) | (968,383) |
| Net loss before income taxes | (13,876,277) | (2,237,988) | (28,523,232) | (3,808,163) |
| Income tax provision | — | — | — | — |
| Net loss | (13,876,277) | (2,237,988) | (28,523,232) | (3,808,163) |
| Net loss per share: | ||||
| Basic and diluted | (0.26) | (0.06) | (0.54) | (0.10) |
| Weighted average number of shares outstanding | ||||
| Basic and diluted | 54,112,845 | 37,784,611 | 52,767,635 | 37,784,611 |
Condensed Balance Sheets (Unaudited)
| Description | June 30, 2026 (Unaudited) | December 31, 2025 |
|---|---|---|
| Assets | ||
| Current Assets | ||
| Cash | 4,923,504 | 2,477,122 |
| Accounts receivable | 26,584 | 51,889 |
| Inventories, net | 787,479 | 918,359 |
| Prepaid assets | 1,255,080 | 46,192 |
| Total Current Assets | 6,992,647 | 3,493,562 |
| Property and equipment, net | 9,258,482 | 8,201,957 |
| Right-of-use assets | 1,093,493 | 1,271,638 |
| Other assets | 273,622 | 53,625 |
| Total assets | 17,618,244 | 13,020,782 |
| Liabilities and stockholders’ equity | ||
| Current Liabilities | ||
| Accounts payable | 1,321,695 | 2,041,908 |
| Accrued liabilities | 413,216 | 431,659 |
| Accrued liabilities, related party | — | 428,278 |
| Employee loan payable, related party | 121,739 | 121,739 |
| Note payable related party | 50,000 | 50,000 |
| Note payable current portion | — | 7,166 |
| Convertible notes payable, net of debt discount current portion | 9,348,543 | 284,146 |
| Warrant liability, at fair value | 2,547,702 | — |
| Operating lease liability current portion | 387,521 | 372,665 |
| Financing lease liability current portion | 1,037,003 | 893,710 |
| Total current liabilities | 15,227,419 | 4,631,271 |
| Long-term liabilities: | ||
| Note payable | — | 27,523 |
| Convertible notes payable, net of debt discount | — | 201,215 |
| Operating lease liability net of current portion | 791,469 | 988,471 |
| Financing lease liability net of current portion | 229,697 | 767,822 |
| Total liabilities | 16,248,585 | 6,616,302 |
| Commitments and contingencies (Note 17) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value, 1,000,000 authorized, no shares issued and outstanding as of June 30, 2026 and December 31, 2025, respectively | — | — |
| Common stock, $0.0001 par value, 500,000,000 and 100,000,000 authorized, 49,152,702 and 44,500,111 shares issued and outstanding as of June 30, 2026 and December 31, 2025 respectively | 4,915 | 4,450 |
| Additional paid-in capital | 65,131,098 | 41,643,152 |
| Accumulated deficit | (63,766,354) | (35,243,122) |
| Total stockholders’ equity | 1,369,659 | 6,404,480 |
| Total liabilities and stockholders’ equity | 17,618,244 | 13,020,782 |
Condensed Statements of Cash Flows (Unaudited)
| Description | Six months ended June 30, 2026 | Six months ended June 30, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | (28,523,232) | (3,808,163) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Stock-based compensation | 21,962,399 | — |
| Issuance of stocks for services | 184,008 | — |
| Depreciation and amortization | 682,374 | 665,743 |
| Amortization of debt discount | 129,278 | 135,565 |
| Amortization of debt discount warrant feature and OID interest | 1,559,510 | 433,458 |
| Change in fair value of warrant liability | (45,094) | — |
| Amortization of deferred financing costs | 191,590 | — |
| Non-cash PIK interest | 30,393 | 143,731 |
| Loss on sale of asset | (56,215) | (1,906) |
| Right-of-use assets, net of lease liabilities | (4,001) | 2,146 |
| Changes in operating assets and liabilities: | ||
| Accounts receivable | 25,305 | 11,825 |
| Inventories | 130,880 | 1,120,416 |
| Prepaid and other current assets | (1,208,888) | (14,985) |
| Accounts payable | (720,214) | 567,390 |
| Accrued liabilities | 330,703 | 234,508 |
| Accrued liabilities, related party | (428,278) | (6,200) |
| Contract liabilities | — | (54,410) |
| Net cash used in operating activities | (5,759,482) | (570,882) |
| Cash flows from investing activities: | ||
| Proceeds from sale of assets | — | 78,000 |
| Capitalized expenditures | (1,682,684) | (88,368) |
| Net cash used in investing activities | (1,682,684) | (10,368) |
| Cash flows from financing activities: | ||
| Proceeds from convertible notes payable | 10,150,000 | 1,350,000 |
| Principal payments on financing lease | (598,766) | (597,117) |
| Proceeds from issuance on equity offerings | 1,342,003 | — |
| Payments on note payable | (34,689) | (564) |
| Debt issuance and deferred direct listing costs | (970,000) | — |
| Net cash provided by financing activities | 9,888,548 | 752,319 |
| Net change to cash | 2,446,382 | 171,069 |
| Cash, beginning of period | 2,477,122 | 434,613 |
| Cash, end of period | 4,923,504 | 605,682 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for interest | 203,009 | 262,496 |
| Supplemental non-cash financing activities | ||
| Original issue discount on debt | 5,465,385 | — |
| Warrant liabilities recognized as debt discounts | 2,592,796 | — |
| Issuance of warrants in conjunction with convertible notes payable | — | 586,813 |
Amounts as printed on the EDGAR/iXBRL face. Labels, columns, and figures are the filing face, not a GAAP stencil. Interactive statements & notes on EDGAR ↗